Literature DB >> 29957233

Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant.

Priyanka Garg1, Angelos Oikonomopoulos1, Haodong Chen1, Yingxin Li1, Chi Keung Lam1, Karim Sallam1, Marco Perez2, Robert L Lux3, Michael C Sanguinetti4, Joseph C Wu5.   

Abstract

BACKGROUND: The long QT syndrome (LQTS) is an arrhythmogenic disorder of QT interval prolongation that predisposes patients to life-threatening ventricular arrhythmias such as Torsades de pointes and sudden cardiac death. Clinical genetic testing has emerged as the standard of care to identify genetic variants in patients suspected of having LQTS. However, these results are often confounded by the discovery of variants of uncertain significance (VUS), for which there is insufficient evidence of pathogenicity.
OBJECTIVES: The purpose of this study was to demonstrate that genome editing of patient-specific induced pluripotent stem cells (iPSCs) can be a valuable approach to delineate the pathogenicity of VUS in cardiac channelopathy.
METHODS: Peripheral blood mononuclear cells were isolated from a carrier with a novel missense variant (T983I) in the KCNH2 (LQT2) gene and an unrelated healthy control subject. iPSCs were generated using an integration-free Sendai virus and differentiated to iPSC-derived cardiomyocytes (CMs).
RESULTS: Whole-cell patch clamp recordings revealed significant prolongation of the action potential duration (APD) and reduced rapidly activating delayed rectifier K+ current (IKr) density in VUS iPSC-CMs compared with healthy control iPSC-CMs. ICA-105574, a potent IKr activator, enhanced IKr magnitude and restored normal action potential duration in VUS iPSC-CMs. Notably, VUS iPSC-CMs exhibited greater propensity to proarrhythmia than healthy control cells in response to high-risk torsadogenic drugs (dofetilide, ibutilide, and azimilide), suggesting a compromised repolarization reserve. Finally, the selective correction of the causal variant in iPSC-CMs using CRISPR/Cas9 gene editing (isogenic control) normalized the aberrant cellular phenotype, whereas the introduction of the homozygous variant in healthy control cells recapitulated hallmark features of the LQTS disorder.
CONCLUSIONS: The results suggest that the KCNH2T983I VUS may be classified as potentially pathogenic.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  arrhythmia; genome editing; induced pluripotent stem cells; long QT syndrome; variant of uncertain significance

Mesh:

Substances:

Year:  2018        PMID: 29957233      PMCID: PMC6050025          DOI: 10.1016/j.jacc.2018.04.041

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  34 in total

Review 1.  Clinical practice. Long-QT syndrome.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2008-01-10       Impact factor: 91.245

2.  Prevalence of the congenital long-QT syndrome.

Authors:  Peter J Schwartz; Marco Stramba-Badiale; Lia Crotti; Matteo Pedrazzini; Alessandra Besana; Giuliano Bosi; Fulvio Gabbarini; Karine Goulene; Roberto Insolia; Savina Mannarino; Fabio Mosca; Luigi Nespoli; Alessandro Rimini; Enrico Rosati; Patrizia Salice; Carla Spazzolini
Journal:  Circulation       Date:  2009-10-19       Impact factor: 29.690

3.  Effects of an hERG activator, ICA-105574, on electrophysiological properties of canine hearts.

Authors:  Mahoko Asayama; Junko Kurokawa; Kiyoshi Shirakawa; Hisashi Okuyama; Toshiki Kagawa; Jun-ichi Okada; Seiryo Sugiura; Toshiaki Hisada; Tetsushi Furukawa
Journal:  J Pharmacol Sci       Date:  2012-12-14       Impact factor: 3.337

Review 4.  Long QT syndrome: reduced repolarization reserve and the genetic link.

Authors:  D M Roden
Journal:  J Intern Med       Date:  2006-01       Impact factor: 8.989

5.  Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test.

Authors:  Jamie D Kapplinger; David J Tester; Benjamin A Salisbury; Janet L Carr; Carole Harris-Kerr; Guido D Pollevick; Arthur A M Wilde; Michael J Ackerman
Journal:  Heart Rhythm       Date:  2009-06-23       Impact factor: 6.343

6.  Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing.

Authors:  Yongming Wang; Ping Liang; Feng Lan; Haodi Wu; Leszek Lisowski; Mingxia Gu; Shijun Hu; Mark A Kay; Fyodor D Urnov; Rami Shinnawi; Joseph D Gold; Lior Gepstein; Joseph C Wu
Journal:  J Am Coll Cardiol       Date:  2014-08-05       Impact factor: 24.094

7.  Low penetrance in the long-QT syndrome: clinical impact.

Authors:  S G Priori; C Napolitano; P J Schwartz
Journal:  Circulation       Date:  1999-02-02       Impact factor: 29.690

8.  Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.

Authors:  Ashish Mehta; Glen Lester Sequiera; Chrishan J A Ramachandra; Yuliansa Sudibyo; Yingying Chung; Jingwei Sheng; Keng Yean Wong; Teng Hong Tan; Philip Wong; Reginald Liew; Winston Shim
Journal:  Cardiovasc Res       Date:  2014-03-12       Impact factor: 10.787

9.  High prevalence of four long QT syndrome founder mutations in the Finnish population.

Authors:  Annukka Marjamaa; Veikko Salomaa; Christopher Newton-Cheh; Kimmo Porthan; Antti Reunanen; Hannu Karanko; Antti Jula; Päivi Lahermo; Heikki Väänänen; Lauri Toivonen; Heikki Swan; Matti Viitasalo; Markku S Nieminen; Leena Peltonen; Lasse Oikarinen; Aarno Palotie; Kimmo Kontula
Journal:  Ann Med       Date:  2009       Impact factor: 4.709

10.  Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes.

Authors:  Elena Matsa; James E Dixon; Christopher Medway; Orestis Georgiou; Minal J Patel; Kevin Morgan; Paul J Kemp; Andrew Staniforth; Ian Mellor; Chris Denning
Journal:  Eur Heart J       Date:  2013-03-06       Impact factor: 29.983

View more
  36 in total

1.  A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.

Authors:  Timon Seeger; Rajani Shrestha; Chi Keung Lam; Caressa Chen; Wesley L McKeithan; Edward Lau; Alexa Wnorowski; George McMullen; Matthew Greenhaw; Jaecheol Lee; Angelos Oikonomopoulos; Soah Lee; Huaxiao Yang; Mark Mercola; Matthew Wheeler; Euan A Ashley; Fan Yang; Ioannis Karakikes; Joseph C Wu
Journal:  Circulation       Date:  2019-02-05       Impact factor: 29.690

Review 2.  Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms.

Authors:  Li Pang; Philip Sager; Xi Yang; Hong Shi; Frederick Sannajust; Mathew Brock; Joseph C Wu; Najah Abi-Gerges; Beverly Lyn-Cook; Brian R Berridge; Norman Stockbridge
Journal:  Circ Res       Date:  2019-10-10       Impact factor: 17.367

Review 3.  Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as Models for Cardiac Channelopathies: A Primer for Non-Electrophysiologists.

Authors:  Priyanka Garg; Vivek Garg; Rajani Shrestha; Michael C Sanguinetti; Timothy J Kamp; Joseph C Wu
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

4.  Patient-independent human induced pluripotent stem cell model: A new tool for rapid determination of genetic variant pathogenicity in long QT syndrome.

Authors:  Nikhil V Chavali; Dmytro O Kryshtal; Shan S Parikh; Lili Wang; Andrew M Glazer; Daniel J Blackwell; Brett M Kroncke; Moore Benjamin Shoemaker; Bjorn C Knollmann
Journal:  Heart Rhythm       Date:  2019-04-18       Impact factor: 6.343

Review 5.  Induced pluripotent stem cells as a platform to understand patient-specific responses to opioids and anaesthetics.

Authors:  Detlef Obal; Joseph C Wu
Journal:  Br J Pharmacol       Date:  2020-08-27       Impact factor: 8.739

Review 6.  Non-viral reprogramming and induced pluripotent stem cells for cardiovascular therapy.

Authors:  Arunima Panda; Narasimman Gurusamy; Sheeja Rajasingh; Hannah-Kaye Carter; Edwin L Thomas; Johnson Rajasingh
Journal:  Differentiation       Date:  2020-01-10       Impact factor: 3.880

Review 7.  Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.

Authors:  Nazish Sayed; Mohamed Ameen; Joseph C Wu
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

Review 8.  Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.

Authors:  Gary Gintant; Paul Burridge; Lior Gepstein; Sian Harding; Todd Herron; Charles Hong; José Jalife; Joseph C Wu
Journal:  Circ Res       Date:  2019-09-19       Impact factor: 17.367

Review 9.  Human iPSC modeling of heart disease for drug development.

Authors:  Anna P Hnatiuk; Francesca Briganti; David W Staudt; Mark Mercola
Journal:  Cell Chem Biol       Date:  2021-03-18       Impact factor: 8.116

Review 10.  Therapeutic genome editing in cardiovascular diseases.

Authors:  Masataka Nishiga; Lei S Qi; Joseph C Wu
Journal:  Adv Drug Deliv Rev       Date:  2020-02-21       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.